Ser33

Site Information
LGsREDQsAKAGGCC SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 12738492

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 )
Relevant cell line - cell type - tissue:	'3T3-L1, differentiated' (adipocyte) ( 2 ) , 'fat, brown' ( 4 ) , BaF3 ('B lymphocyte, precursor') [JAK3 (human), transfection] ( 1 ) , kidney ( 4 ) , lung ( 4 ) , macrophage-peritoneum ( 3 ) , RAW 267.4 (macrophage) ( 5 ) , spleen ( 4 )

Upstream Regulation
Treatments:	IFN-gamma ( 5 )

References
1	Degryse S, et al. (2017) Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia. Leukemia 32 28852199 Curated Info
2	Humphrey SJ, et al. (2013) Dynamic Adipocyte Phosphoproteome Reveals that Akt Directly Regulates mTORC2. Cell Metab 17, 1009-20 23684622 Curated Info
3	Wu X, et al. (2012) Investigation of receptor interacting protein (RIP3)-dependent protein phosphorylation by quantitative phosphoproteomics. Mol Cell Proteomics 11, 1640-51 22942356 Curated Info
4	Huttlin EL, et al. (2010) A tissue-specific atlas of mouse protein phosphorylation and expression. Cell 143, 1174-89 21183079 Curated Info
5	Trost M, et al. (2009) The phagosomal proteome in interferon-gamma-activated macrophages. Immunity 30, 143-54 19144319 Curated Info